Q1 2023 Results slide image

Q1 2023 Results

Company overview Financial review Conclusions Innovation: Pipeline overview Financial performance Cardiovascular Immunology Neuroscience Appendix Innovation: Clinical trials Neuroscience Oncology References Abbreviations Other 63 Investor Relations | Q1 2023 Results NOVARTIS | Reimagining Medicine
View entire presentation